GlassScriptPhysician profile
Carmen Dohmeier
NPI 1588620066
$13,366.57
in general payments reported to CMS, 2019-2025
72 companies · $3,374 in 2025
The $3,374 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,041 · 2020: $366 · 2021: $583 · 2022: $835 · 2023: $3,024 · 2024: $3,145 · 2025: $3,374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,390 · Travel and Lodging: $1,108 · Education: $45.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,389.51 |
| Travel and Lodging | $1,108.01 |
| Education | $45.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $1,811.41 | 2019-2025 | Mavenclad, Mavenclad |
| Inspire Medical Systems, INC. | $1,274.61 | 2023-2025 | Inspire |
| Abbvie INC. | $916.27 | 2021-2025 | Botox, Qulipta, Ubrelvy |
| Ucb, INC. | $704.18 | 2019-2025 | Briviact, Rystiggo, Zilbrysq |
| Novartis Pharmaceuticals Corporation | $686.10 | 2019-2025 | |
| Biogen, INC. | $653.99 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Harmony Biosciences LLC | $497.95 | 2020-2025 | Wakix |
| Amgen INC. | $464.49 | 2019-2025 | Uplizna, Aimovig |
| Jazz Pharmaceuticals INC. | $377.04 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $350.90 | 2021-2025 | Zeposia |
| Genzyme Corporation | $299.25 | 2019-2025 | |
| Tg Therapeutics, INC. | $281.23 | 2023-2025 | |
| Neurelis, INC. | $278.93 | 2021-2025 | Valtoco |
| Lundbeck LLC | $275.22 | 2020-2025 | Vyepti, Rexulti |
| Alexion Pharmaceuticals, INC. | $262.02 | 2020-2025 | Ultomiris, Soliris |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmen Dohmeier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.